Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Clene (CLNN) just unveiled an update.
Clene Inc. made a significant announcement on June 17, 2024, at the ENCALS Meeting, presenting promising clinical results of their CNM-Au8® treatment in an ongoing ALS trial. The next day, the company further publicized the extended survival data and new findings regarding neurofilament light responder results from the same trial, reinforcing the potential impact of their treatment on ALS patients, and sparking interest among investors and the wider public eyeing advancements in medical treatments.
For an in-depth examination of CLNN stock, go to TipRanks’ Stock Analysis page.
